PaxVax, Inc. Announces Positive Results for Oral Ad4 Vaccine Technology  
1/31/2013 10:29:45 AM

MENLO PARK, Calif.--(BUSINESS WIRE)--PaxVax, Inc., which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced positive results in a Phase 1 clinical trial for its oral, replicating adenovirus serotype 4 (Ad4) vector vaccine for H5N1 (avian flu). The results have been published in the journal Lancet Infectious Diseases (published online January 29, 2013). The study was funded by The Wellcome Trust.